Derivation of doxorubicin mutational signatures in cancer
Genome Research · 10.11.2026
DOI: 10.1101/gr.281868.126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genome Research, online erschienen am 10.11.2026. Verfasst von Katie T Skinner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, USA. Gefördert von: National Cancer Institute, U.S. Department of Defense, American Cancer Society.
Abstract (Originalsprache)
Doxorubicin is a chemotherapeutic agent used for the treatment of solid and hematopoietic malignancies. Doxorubicin acts as a DNA intercalator and inhibits the topoisomerase II enzyme, leading to double-stranded breaks. We hypothesize that doxorubicin mutagenesis leads to a nonrandom pattern of somatic mutations on the genome, termed a mutational signature. We expose cells to doxorubicin using two different methodologies: (1) continuous exposure of a constant dose of doxorubicin and whole-genome sequencing of single-cell clones (previously published methodology) and (2) pulsed exposure of escalating doses of doxorubicin and whole-genome sequencing of a bulk population. We first confirm that the methodologies do not yield differing results through previously published cisplatin-exposed single-cell clone genome data compared with the dose escalation and bulk genome data. We then derive two doxorubicin signatures. The first, SBS-doxorubicin-1, is defined by an abundance of C > A mutations. The second, SBS-doxorubicin-2, is defined by a higher occurrence of T > C mutations. We then assess for the presence of our signatures within the genomes of patients treated with a doxorubicin-containing regimen. Across 10 bulk immune sorted samples from three patients with follicular lymphoma/diffuse large B cell lymphoma, as well as two metastatic samples from one patient with renal medullary carcinoma, we are able to detect both signatures in 83% of samples, with remaining samples harboring either signature. In summary, we experimentally derive two doxorubicin mutational signatures and demonstrate their presence in patient samples.
Autor:innen und Institutionen
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
- Aflac Cancer and Blood Disorders Center-Children's Healthcare of Atlanta, Atlanta, Georgia 30329, USA.
- Department of Computer Science, Emory University, Atlanta, Georgia 30322, USA.
- Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore 169857, Singapore.
- Centre for Biomedical Data Science, Duke-NUS Medical School, Singapore 169857, Singapore.
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, USA; andrew.hong2@emory.edu.
Förderung
- National Cancer Institute
- U.S. Department of Defense
- American Cancer Society
- Ian's Friends Foundation
- CURE Foundation
Zitieren
APA
Skinner, K. T., Lee, B. P., Woods, C. W., Yoon, J. S., Ho, S. C., Boot, A., Yu, W., Rozen, S. G., & Hong, A. L. (2026). Derivation of doxorubicin mutational signatures in cancer. Genome Research. https://doi.org/10.1101/gr.281868.126
Vancouver
Skinner KT, Lee BP, Woods CW, Yoon JS, Ho SC, Boot A, et al. Derivation of doxorubicin mutational signatures in cancer. Genome Research. 2026. doi:10.1101/gr.281868.126
BibTeX
@article{Skinner2026,
author = {Skinner, Katie T and Lee, Benjamin P and Woods, Carson W and Yoon, Jessica S and Ho, Szu-Chi and Boot, Arnoud and Yu, Willie and Rozen, Steven G and Hong, Andrew L},
title = {Derivation of doxorubicin mutational signatures in cancer},
journal = {Genome Research},
year = {2026},
doi = {10.1101/gr.281868.126}
}
EUVIMED